EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Institute of Oncology Ljubljana
Liubliana, EsloveniaPublicaciones en colaboración con investigadores/as de Institute of Oncology Ljubljana (3)
2022
-
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population (Breast Cancer Research and Treatment, (2021), 189, 3, (689-699), 10.1007/s10549-021-06334-0)
Breast Cancer Research and Treatment
2021
-
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Breast Cancer Research and Treatment, Vol. 189, Núm. 3, pp. 689-699
2013
-
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer
Journal of Clinical Oncology, Vol. 31, Núm. 20, pp. 2586-2592